Idorsia Ltd (OTCMKTS:IDRSF) Sees Large Drop in Short Interest

Idorsia Ltd (OTCMKTS:IDRSF) was the target of a significant drop in short interest during the month of October. As of October 15th, there was short interest totaling 6,184,041 shares, a drop of 35.0% from the September 30th total of 9,515,618 shares. Based on an average trading volume of 2,261 shares, the short-interest ratio is currently 2,735.1 days.

Idorsia Stock Performance

Shares of OTCMKTS IDRSF opened at $4.95 on Tuesday. The business has a fifty day simple moving average of $5.80 and a 200 day simple moving average of $5.67. Idorsia has a one year low of $3.50 and a one year high of $8.19.

Analyst Upgrades and Downgrades

Several research firms recently commented on IDRSF. HC Wainwright reiterated a “buy” rating on shares of Idorsia in a research note on Monday, September 14th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Idorsia in a report on Monday, August 3rd. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy”.

Idorsia Company Profile

Idorsia Ltd. is a Swiss biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. Its research activities span areas including cardiovascular disease, central nervous system disorders, immunology and rare diseases. The company operates from its headquarters in Allschwil, Switzerland, and serves international pharmaceutical markets through its own commercial operations and collaboration arrangements.

Idorsia’s commercial portfolio includes QUVIVIQ (daridorexant), an orexin receptor antagonist used to treat insomnia in eligible adults, and PIVLAZ (clazosentan), a therapy intended to reduce the risk of cerebral vasospasm and related complications following aneurysmal subarachnoid hemorrhage.